A study published on Frontiers demonstrated how CXCL12 chemokine plays a pivotal role in various physiological processes, including hematopoiesis, organogenesis, and tissue regeneration.
A recent study has highlighted the role of HMGB1 as a potential mediator in the development of postoperative delirium.
HMGB1 role in Postoperative Delirium Read More »
In literature has been demonstrates that HMGB1 induces cell migration by activating RAGE or CXCR4 receptor through a heterologous complex with CXCL12.
Spinal cord injury: HMGB1 heterologous complex with SDF1 (CXCL12) Read More »
A recent study in the journal Frontiers underscores the association between HMGB1 and autophagy in the progression and complications of diabetes mellitus.
HMGB1 and autophagy relationship in the pathogenesis of diabetes Read More »
HMGB1, proinflammatory mediator belonging to the alarmin family, is making waves in asthma research.
During tissue inflamation, HMGB1 protein is secreted by various immune cells and has a dual way of entering the extracellular space.
Asthma research update: the pivotal role of HMGB1 Read More »
HMGBiotech has joined the conference “Goodbye Flat Biology: Next Generation Cancer Models” promoted by EACR, through a poster presentation by Dr. Andrea Lamarca.
Speech at Berlin EACR Conference: Mesothelioma and HMGB1 BoxA Read More »
A recent research has highlighted a groundbreaking discovery concerning the connection between HMGB1 released by mesothelial cells and the development of asbestos-induced mesothelioma.
Unveiling the Mechanism Behind Asbestos-Induced Mesothelioma Read More »
Liam Colley, HMGBiotech’s researcher, gave a speech about “The role of CXCR4 in Triggering Immunosurveillance in the Malignant Mesothelioma Tumor Environment”.
HMGBiotech at CICON- International Cancer Immunotherapy Conference 2023 Read More »
HMGB1 has been shown to play a key role in Parkinson’s disease pathogenesis. Research and studies targeting High Mobility Group Box 1 (HMGB1) protein in Parkinson’s disease (PD) has recently emerged, with promising results in the inhibition of HMGB1.
HMGB1, a Potential Game-Changer in Parkinson’s Research Read More »
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for experience, measurement and marketing (personalised ads) as specified in the cookie policy. You can freely give, deny, or withdraw your consent at any time by accessing the preferences panel. Denying consent may make related features unavailable. Use the “Accept” button to consent. Use the “Reject” button or close this notice to continue without accepting.